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Motor neuron disease (MND) is a devastating neurodegenerative disorder, with recognised 
phenotypic subtypes. Although prevalent in all parts of the world, little is described in the literature 
with regards motor neuron disease as it occurs in African populations. 
Aims 
This study had two main aims: to conduct a systematic review of the current available literature on 
motor neuron disease in persons of African genetic descent, and to describe the clinical phenotype 
in a subgroup of MND patients with the flail arm (FA) variant seen at Groote Schuur Hospital MND 
clinic. 
Methods 
In order to identify the current published knowledge of motor neuron disease in African populations, 
a systematic literature review was conducted using Pubmed and Google Scholar. For the case series 
description, patients presenting to the Groote Schuur Hospital MND clinic with a phenotype of 
restricted proximal upper limb, lower motor neuron involvement for at least 12 months after 
symptom onset, during the time period of March 2014 to September 2016, were considered for 
inclusion. A full clinical description of each case, including history, examination and 
electrophysiological findings, was conducted. 
Results 
Review of the available literature on MND as it occurs in persons with African ancestry revealed that 
little is well described. Although there are a few original studies, all are small and most are out-
dated. Some trends emerged, including younger age at onset of disease, tendency to longer survival, 
and possibly more frequent presentation with bilateral upper limb involvement.  
Six cases of FA variant of MND, representing 13% of the MND clinic cohort seen over the 2.5 years 
given time period, all with African genetic ancestry by self-categorization (mixed in 5, pure African in 
1), are reported illustrating the various previously described features of this phenotype. Even within 
these few cases, there is variation in presentation and disease course. 
Conclusions 
More research is required on African populations to address the questions surrounding MND as it 
occurs in Africans, including phenotypic and genetic similarities or differences to other populations. 
Although controversy surrounding exact case definition of the FA variant of MND remains, it does 
represent a unique phenotype, and seems to occur in patients of African genetic ancestry in a similar 
manner to that described in Caucasian populations.  
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1. Introduction and problem identification 
 
Motor neuron disease (MND) is a devastating neurodegenerative disorder prevalent in all parts of 
the world. Aetiology is still poorly understood and is likely multifactorial. The role of genetic variants 
may be an important factor and is currently a much researched topic. 
 
Most literature on the subject reports on Caucasian populations from developed countries. Little is 
described in the literature with regards motor neuron disease in African populations. This includes 
basic epidemiological data, clinical phenotypes, and the more recently topical, associated genetic 
findings. 
 
South Africa has genetically diverse sub-populations, the vast majority of which have African genetic 
ancestry. 
 
Motor neuron disease is not infrequently seen at Groote Schuur Hospital, one of the main referral 
centres in the Western Cape. A specialised motor neuron disease clinic has recently been 





2. Rationale and Motivation:  
Background to the study with review of the literature 
 
2.1 Motor neuron disease 
 
Motor neuron disease or amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of both 
upper and lower motor neurons, involving bulbar, cervical, thoracic and lumbosacral regions. 
Although there is variation in onset and progression, the disease is invariably fatal. The majority of 
cases are sporadic, although current reported rates of familial ALS are about 5-10% of cases (Kiernan 
et al., 2011). 
  
The clinical hallmark of classic ALS is the simultaneous presence of upper and lower motor neuron 
signs involving the brain, brainstem and multiple spinal cord levels.  Onset typically occurs in one 
region, with subsequent spread to other regions. Limb onset is most common (70%), followed by 
bulbar (25%) and then respiratory (5%) (Kiernan et al., 2011). Emotional lability and frontal lobe type 
cognitive impairment are also frequently part of the presentation (Kiernan et al., 2011). 
 
MND is considered the third most common neurodegenerative disease, after Alzheimer’s disease 
and idiopathic Parkinson’s disease (Renton et al., 2014). It occurs worldwide, although the current 
literature does not allow for appreciation of global incidence or prevalence statistics. European 
population-based studies estimate the incidence to be about 2.16/100000 person-years  (Kiernan et 
al., 2011). There appears to be a slight male predominance in sporadic ALS. In familial ALS there is 
equal incidence between the sexes (Kiernan et al., 2011).The peak age range in current reported 
literature for the onset of sporadic ALS, is 58-63 years, and 47-52 years in familial ALS (Kiernan et al., 
2011). 
 
MND remains a clinical diagnosis. There are no reliable laboratory nor imaging biomarkers. In 1994 
diagnostic criteria were devised by the World Federation of Neurology working group on Motor 
Neuron Diseases, primarily for use in the research setting. These criteria are known as the El Escorial 
criteria (Brooks, 1994). They described four levels of diagnostic certainty in MND – definite, 
probable, possible and suspected, based on the distribution of mixed upper and lower motor neuron 
(U/LMN) signs within body regions (bulbar, cervical, thoracic and lumbosacral). “Definite” required 
UMN and LMN signs in three regions, “probable” required UMN and LMN signs in two regions, 
“possible” one region, whilst “suspected” was reserved for those with only LMN signs. These criteria 
were updated at Airlie House in 2000 and Awaji-Shima in 2008. In 2000, the “suspected” category 
was removed and a “laboratory-supported probable” category was added, which allowed 
electrophysiological evidence of LMN involvement to be considered in the probable category 
(Brooks et al., 2000). The 2008 Awaji criteria broadened the use of electrophysiological evidence of 
LMN involvement to all categories (Carvalho and Swash, 2009). (See table 1 (Al-Chalabi et al., 2016)). 
Despite multiple revisions these criteria still lack sensitivity and importantly, whilst defining ALS, they 

















Table 1: The El Escorial criteria and its revisions, taken from (Al-Chalabi et al., 2016) 
 
2.2 Disease variants 
 
Distinct disease phenotypes within MND are recognised. The first to be described and probably still 
the best characterised are the classic limb onset ALS, progressive bulbar palsy and progressive 
muscular atrophy phenotypes. 
 
In classic limb onset ALS, symptoms are first noted by the patient in the upper or lower limbs (often 
with more widespread signs than symptoms) followed fairly rapidly by involvement of other 
segments such as bulbar or respiratory muscles. Progressive bulbar palsy, as the name suggests, 
starts with prominent weakness of the bulbar musculature before spreading to other regions. This 
phenotype has consistently been linked with a poorer prognosis and appears to be more common in 
women (Kiernan et al., 2011). In progressive muscular atrophy (PMA), there is exclusive lower motor 
neuron involvement. This subtype of MND typically has a longer survival. Primary lateral sclerosis 
(PLS) is a purely upper motor neuron variant of MND, but is extremely rare. Definitive diagnosis of 
this variant should be delayed at least 4 years, as lower motor neuron features could develop during 
this time (Gordon et al., 2006). 
 
Two further MND variants were more recently included: flail arm (FA) and flail leg variant.  These 
represent lower motor neuron disorders of the upper and lower limb respectively. In the FA variant 
weakness and wasting occur proximally and fairly symmetrically in the upper limbs. In contrast, the 
flail leg variant is characterised by predominant distal involvement in the lower extremities.   
 
A final phenotypic variant to be mentioned is Mill’s variant (also known as hemiplegic ALS), in which 
there is a predominant upper motor neuron, hemiplegic pattern of involvement. It is controversial 
whether this is a true subtype or merely a descriptive clinical pattern of PLS disease onset (Ravits et 
al., 2013). 
 
The flail arm variant was first described by Vulpian in 1886 and Gowers in 1888 and has been 
recognised under several names: Vulpian-Bernhardt Syndrome, brachial amyotrophic diplegia, 
hanging-arm syndrome, dangling arm syndrome or neurogenic man-in-the-barrel syndrome. The 
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variant accounted for about 10% of MND patients at one referral centre (Hu et al., 1998). Given the 
prominent, symmetrical involvement of the proximal arm muscles with sparing of the legs and 
bulbar muscles it is an easily clinically recognisable phenotype. There may be milder distal upper 
limb weakness (in contrast to the more severe distal weakness and wasting of limb onset ALS). It has 
been shown to have more of a male predominance than other MND variants (Wijesekera et al., 
2009, Hu et al., 1998). 
 
Bilateral arm weakness may be the presenting feature in classic limb onset ALS in 5-10% of such 
cases, yet in FA variant (see definition below) the pattern of weakness remains more restricted over 
time (Katz et al., 1999). Flail arm variant has been shown to differ from upper limb onset ALS in 
terms of distribution and severity of weakness and wasting at presentation (Yoon et al., 2014). While 
ALS presents with prominent distal arm weakness and the FA variant with proximal weakness, both 
show similar age at onset and electrophysiological findings (Yoon et al., 2014). Additionally, studies 
have shown pathology typical of ALS in the flail arm subgroup (Sasaki, 2007), although 
predominantly restricted to the cervical region. 
 
There are two schools of thought with regards the exact definition of this phenotype. Wijesekera et 
al describe a more widely inclusive flail arm variant in which some cases have pathological deep 
tendon reflexes and whilst remaining restricted to the upper limbs for 12 months post onset of 
symptoms, many patients (22-77%) will eventually develop signs in the lower limbs and bulbar 
regions (Wijesekera et al., 2009). They argue that the FA phenotype is associated with a significantly 
improved survival, which appears to be linked to time to spread to the second region of involvement 
(Wijesekera et al., 2009). 
 
Katz et al (Katz et al., 1999) are more restrictive in their definition and label the syndrome brachial 
amyotrophic diplegia. They describe a case series of 10 such patients by including those with lower 
motor neuron signs confined to the arms for more than 18 months. Seven of these patients had a 
relatively stable course after an initial rapid deterioration, and failed to develop signs outside of the 
upper limbs after a mean follow-up of 67 months. Nine out of ten were completely pure lower 
motor neuron syndromes. On the basis of their findings, they argue that there may be a subgroup 
even within the FA variant which has greatly improved survival. They propose that this group could 
perhaps rather be considered a variant of PMA than of ALS as a whole. 
 
2.3 Aetiology and neuropathology 
 
The pathophysiological mechanisms underlying motor neuron disease are not yet fully elucidated. It 
seems most likely to be due to multifactorial processes with complex interactions between genetic 
and molecular pathways (Kiernan et al., 2011). 
 
What is clear, is that there is loss of upper and lower motor neurons, with axonal degeneration along 
their projection course from the motor cortex to the lateral columns (“lateral sclerosis”) and from 
the anterior horn cells to the peripheral nerves, leading to denervation of muscles (“amyotrophic”). 
There are also changes in the neuronal support cells (astrogliosis, spongiosis and microglial 
activation), but whether these changes are part of the pathological process or merely secondary is 




In 1988 Leigh et al and Lowe et al (Leigh et al., 1988, Lowe et al., 1988) identified the deposition of 
ubiquitin in the cytoplasm of ALS motor neurons. Ubiquitin is known to have a maintenance-type 
role within the cell, in the realm of protein homeostasis. It was suggested that perhaps a 
pathological protein was being identified for removal by the cell. Similar changes were also noted in 
brains of patients with frontotemporal dementia. This pathological protein was identified as TDP-43 
in 2006 (Neumann et al., 2006, Arai et al., 2006). TDP-43 is a nuclear protein involved in RNA and 
DNA processing, which in ALS and FTD was being translocated to the cytoplasm and altered into a 
pathological form (Ravits et al., 2013). In the majority of ALS, these ubiquinated inclusions of TDP-43 
are the hallmark of the neuropathology. Other proteins with a role in ALS neuropathology have 
subsequently been discovered, largely in connection with genetic discoveries (see below.) Four main 
neuropathological subtypes are now recognised (Ravits et al., 2013). Firstly TDP-43 proteinopathy 
described above (in the majority of patients). Secondly, C9ORF72 related TDP-43 proteinopathy, 
which is similar but also has deposits of a secondary pathological protein, p62.  The third type is the 
deposition of ubiquinated SOD1 protein. In this group, the pathological burden is greater in the 
lower rather the upper motor neurons. Finally a FUS proteinopathy has basophilic inclusions which 
contain FUS protein (Ravits et al., 2013). 
 
The different neuropathological findings are linked to some extent to the underlying genetic 
abnormality, where identified. The pathology does not seem to vary between the different clinical 
phenotypes, rather there is a differing distribution of disease load, accounting for the phenotypic 
differences (Ravits et al., 2013). That said, the relationship of the phenotype, neuropathology and 
genetics are not yet fully understood.  
 
There appears to be a trigger initiating signalling pathways leading to neurodegeneration, then 
propagation of the pathophysiological process neuroanatomically, and finally neuronal death. It has 
been suggested that the propagation occurs in a prion-like fashion, due to the actions of the 
abnormal proteins. There may also be a role for the neuronal support cells (astrocytes, 
oligodendrocytes and microglia) in terms of handling of toxic substances or non-provision of 
appropriate trophic support. 
 
Pathophysiological processes implicated in MND include glutamate-induced excitotoxicity, oxidative 
stress with the generation of free radicals, disruption of axonal transport systems, mitochondrial 
abnormalities, Na+/K+ pump dysfunction, and as suggested above, insufficient neurotrophic factors, 
excessive neurotoxic compounds, glial cell dysfunction and cytoplasmic protein aggregations 
interfering with RNA and DNA metabolism (Kiernan et al., 2011). All of these mechanisms could 
induce signs of MND but none are able to cause pathology in the scale required for the severity of 
disease when activated alone. This implies a multifactorial process, and that most likely, these are 
not the primary causative factors (Musarò, 2013). 
 
There have been some suggested environmental risk factors which may impact on the above 
processes, possibly with a triggering role. Intensive physical exertion, including professional sport 
and armed service, have been linked to an increased rate of ALS (Harwood et al., 2009, Kasarskis et 
al., 2009, Chiò et al., 2005). Other proposed environmental risk factors include cigarette smoking 
(Gallo et al., 2009), low or high maternal age and “exposure to younger siblings” (Fang et al., 2008). 
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Certain neurotoxins may also play a role as was found in a cohort of MND patients in Guam (Cox and 
Sacks, 2002). A particular neurotoxin suspected to contribute to the development of MND in 
susceptible individuals is beta N methylamino l alanine (BMAA) produced by marine cyanobacteria 
found in blue green algae (Pablo et al., 2009).  
 
 
2.4 Genetics of motor neuron disease: summary of current knowledge 
 
The first gene associated with ALS was superoxide dismutase 1 (SOD1) in 1993 by Rosen et al (Rosen 
et al., 1993). SOD1 has been shown to be associated with about 12% of familial cases and about 1% 
of sporadic cases. There is considerable phenotypic heterogeneity amongst these mutation carriers. 
 
The next ALS gene discovery was not until 2008 when TAR DNA-binding protein (TARDBP) mutations 
were found (Sreedharan et al., 2008). This followed on the discovery of the TDP-43 protein, which is 
a major component of the ubiquitin-positive neuronal inclusions which are now seen as a 
pathological hallmark of ALS and fronto-temporal dementia (FTD) (Neumann et al., 2006). The 
mutation is known to cause about 4% of familial ALS. The characteristic pathology is however much 
more widespread (Renton et al., 2014). 
 
Missense mutations in fused in sarcoma (FUS) gene on chromosome 16 were discovered shortly 
after TARDBP (Kwiatkowski et al., 2009). This mutation causes similar pathology to TDP-43, but with 
FUS inclusions. A similar gene, Ubiquilin2, which was also linked to ALS, encodes the protein which 
regulates proteosome degradation of ubiquitin proteins (Deng et al., 2011). Both these proteins are 
suggested to have a role in the development of protein aggregate inclusions and aberrant RNA 
processing. 
 
Mutations in optineurin (OPTN) were initially described in Japanese familial ALS (Maruyama et al., 
2010) and have remained most common in this population group. This gene has also been 
implicated in the seemingly unrelated disorders of primary open angle glaucoma and Paget’s disease 
of bone (Renton et al., 2014). OPTN regulates many different cellular processes, which may relate to 
its phenotypic variability with mutations. What it perhaps highlights is the concept of ALS as a 
consequence of tissue-specific expression of possibly several interacting pathways. This idea of a 
multisystem proteinopathy was raised when valosin-containing protein (VCP) gene mutations were 
found to cause ALS as well as the syndrome of inclusion body myopathy with Paget’s disease and 
frontotemporal dementia (IBMPFD) (Kim et al., 2013, Johnson et al., 2010).  
 
Sequestosome 1 (SQSTM1) mutations are also linked to ALS (Fecto et al., 2011) and Paget’s disease. 
This gene encodes a protein (p62) that regulates ubiquitin binding and NFKb signalling. 
 
Hexanucleotide repeat expansions in C9orf72 on chromosome 9 (Renton et al., 2011) were 
discovered to cause ALS in 2011. This was an important milestone, as this gene has been shown to 





Mutations in profilin 1 (PFN1) are not a common cause of familial ALS, but were an important 
discovery in that they highlighted a new pathogenic pathway, namely disruption of the neuronal 
cytoskeleton (Wu et al., 2012). 
 
The above mentioned nine genes are the current most established genes linked to ALS. Mutations in 
several other genes (>20 in total) have been raised, but the genetic evidence for a link with ALS is 
weaker (Renton et al., 2014).  
 
With the development of next generation sequencing, it has become possible to examine multiple 
genes associated with ALS in parallel, in a relatively unbiased approach. It has been found that some 
ALS patients carry pathogenic variants in more than one known ALS gene (van Blitterswijk et al., 
2012). Cady and colleagues (Cady et al., 2015) hypothesised that some of the apparently sporadic 
cases of ALS may be due to the co-occurrence of two or more genetic variants with synergistic 
negative effects. This group analysed 17 ALS-associated genes in 391 ALS patients from a US 
database, 10% of which had a family history of ALS; 4% of study participants had variants in more 
than one gene (14% of familial cases, 3% of sporadic cases), supporting their hypothesis. In addition 
to this, novel or rare coding variants were discovered in 64% of the familial and 28% of the sporadic 
cases, highlighting the utility of the current next generation sequencing in furthering our knowledge 
of the genetics of ALS. 
 
Although the focus of this dissertation is on the clinical characterization of MND patients with 
predominant lower motor neuron involvement in the arms, seen at our MND clinic between June 
2014 and September 2016, we also have an opportunity to collaborate with a bioinformatics team to 
use whole exome sequencing (WES) to discover genetic variants in one of these cases and his 
unaffected parents (family trio). The results of the WES will not form part of this dissertation, but I 
will discuss the principles of WES and gene variant discovery as this is potentially a powerful tool to 
discover the molecular underpinning of neurological diseases and will become increasingly available 
in the clinic. 
 
2.5 Whole exome sequencing 
 
Whole exome sequencing (WES) is an application of the next generation sequencing technology that 
involves examining only the protein coding genes, or exome, from the greater genome. The exome 
consists of about 200,000 exons (Ku et al., 2012), which constitutes about 1% of the total human 
genome (Teer and Mullikin, 2010). Exome sequencing can therefore only detect mutations in these 
regions of genes. Although WES has been a successful strategy to identify pathogenic variants in 
monogenic inherited disorders due to truncated or missing protein products, usually in individuals 
with a clear family history such as autosomal dominant or recessive muscular dystrophy, its 
usefulness in sporadic disorders is less clear. The aim of this approach is to identify pathogenic 
variation, both rare causal variants and risk variants, which may be responsible for disease, whilst 
being cheaper than approaches such as whole genome sequencing (Singleton, 2011).  
 
The principle of WES is that a genomic DNA sample is first sheared into small fragments of about 
200bp and then hybridized to prefabricated DNA probes (the capture kit). This helps to separate out 
the exons. The hybridized exons are then captured by antibody marked beads, purified and 
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amplified using PCR via high throughput parallel sequencing. Once sequenced, the genomic data is 
mapped against a reference human genome to identify deviations. Polymorphisms that are found in 
control human databases or predicted to be non pathogenic are excluded. The remaining rare 
variations are then subjected to bioinformatic tools which can predict whether the sequence 
variations are likely to be non-synonymous (result in a change in produced protein) or cause loss of 
protein translation. These would then become potential disease candidates (Singleton, 2011, Glass 
and Nuara, 2013, Narayanaswami, 2015). 
 
 
Figure 1: The process of whole exome sequencing, taken from (Sastre, 2014) 
 
 
Whilst excellent for identifying genes for highly penetrant Mendelian disorders and single nucleotide 
variations, whole exome sequencing may miss variations in non-transcribed regions of the genome 
(such as introns, promoters and regulatory elements), variations that alter mRNA splicing, variations 
regulated epigenetically and variations in the forms of deletions, duplications (including sequence 
repeats) and translocations (Sastre, 2014, Glass and Nuara, 2013). For these possibilities, it would be 






Figure 2: Schematic representation of gene structure and expression (Sastre, 2014) 
 
 
The above figure, taken from (Sastre, 2014), highlights the elements of gene structure and the 
process of transcription. This makes it easy to see that when only examining the exome, important 
regulatory regions are not examined. This could have implication for missing causative gene 
mutations particularly in complex diseases where altered gene dosage may be critical (Nel, 2016). 
 
Exome sequencing is helpful in identifying variants in known disease-causing genes, as well as 
identifying genes not previously known to cause disease (Singleton, 2011). Additionally it is likely to 
be beneficial in finding mutations in genes known to cause disease, but which are phenotypically 
different to that currently being examined. For example, the discovery of the VCP mutation causing 
ALS (Johnson et al., 2010). This gene was previously linked to Paget’s disease of the bone and 









3. Research Aims and Objectives 
 
3.1 Aims of the study 
 
There were two main aims of this study: 
 
1. To conduct a systematic review of the current available literature on motor neuron disease in 
persons of African genetic descent. 
 
2. To describe the clinical phenotype in a subgroup of MND patients with the flail arm variant seen 
at Groote Schuur Hospital MND clinic between March 2014 and September 2016. 
 
An exploratory aim was to lay the foundations for a genetic sub-study: 
 
To initiate descriptive disease terms, to be used to generate ontological terms, to be used to 
construct an MND-semantic graph for bioinformatic data mining in a subsequent sub-study of an 




1. Current literature on motor neuron disease in African populations is limited, especially for the 
sub-Saharan region. 
 
2. Flail arm variant patients of African ancestry seen at Groote Schuur Hospital, have similar 





4. Research Design and Methods 
 
A dedicated motor neuron disease clinic was established at Groote Schuur Hospital Division of 
Neurology in March 2014 to better provide for the multidisciplinary needs of the hospital’s MND 
patients. This clinic also provides a perfect research opportunity to study this population. All patients 
attending the clinic are approached about being involved in African research into MND. Where 
informed consent is obtained, clinical data is captured and blood samples taken for storage for 
potential genetic analysis. This then forms part of the MND clinical database and DNA repository. 
Within this setting, the current study has taken place. 
 
There are three components to this study: 
 
1. Systematic  review 
 
In order to identify the current published knowledge of motor neuron disease in African populations, 
a systematic literature review was conducted using Pubmed and Google Scholar. The following key 
words in various combinations were used: amyotrophic lateral sclerosis/ALS; motor neuron 
disease/MND; MND/ALS variants; flail arm variant; brachial amyotrophic diplegia; Vulpian-Bernhardt 
syndrome; phenotype; genotype; genetics; exome sequencing; African; Sub Saharan Africa; African-
American; race; ethnicity; differences.  Additional studies were identified through the reference lists 
provided by studies found in the above manner. 
 
2. Clinical phenotype description 
 
Patients presenting to the Groote Schuur Hospital MND clinic with an upper limb, lower motor 
neuron presentation of motor neuron disease, with initial sparing of lower limbs and bulbar 
musculature, during the time period of March 2014 and September 2016, were considered for 
inclusion in the case series. Eligible patients for the FA variant study had symptoms confined to the 
upper limbs (predominantly proximal) for at least 12 months prior to spread to other regions. A full 
clinical description of each case, including history, examination and electrophysiological findings, 
was conducted.  
 
3. Preparation for genetic sub-study 
 
We have the opportunity to participate in a WES study in collaboration with colleagues at the South 
African National Bioinformatics Institute, University of the Western Cape, with the aim of detecting 
novel disease-associated genes using a trio-based approach. Family analysis of case-unaffected 
parent trios is a powerful way to investigate for recessively inherited (homozygous/compound 
heterozygous) or de novo mutations. Both of these mechanisms could give rise to an apparently 
sporadic case of ALS with actual genetic causation (Steinberg et al., 2015).  
 
Two patients from the above case series with the distinct flail arm phenotype of MND were 
consented to specifically participate in a genetic sub-study. One family trio (affected individual with 
both unaffected living parents) were invited to participate and an additional case without living 
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parents. The parents’ DNA was to provide useful control data. Whole exome sequencing will be 
performed on these four participants in an attempt to identify protein coding variants associated 
with flail-arm variant of MND in this population.  
 
To assist our bioinformatics collaborators in the development of a specific BioOntological 
Relationship Graph (BORG) for MND, Dr Helen Cross created a list of clinical terms describing 
phenotypic, anatomic, pathological and genetic features associated with MND (see table 2). These 
terms were converted to official ontology terms and identities (HPO/MPO - Human/mouse 
phenotype ontology) by the genomicists in order to create the disease model in BORG. This database 
is used to assess the likely biological impact of genetic variants. It employs a concept of cross-
ontology linking. Multiple sources of genomic and biomedical knowledge (phenotypes and disease 
pathways) are combined into a semantic network, using standard ontological terms. This allows 
indirect associations to be uncovered via biologically plausible links (Saunders et al., 2016, Dashti et 
al., 2012).  
 
Once identified in the above manner, the candidate variants will be systematically interrogated by 
the clinicians (Dr Helen Cross and Prof Jeannine Heckmann) to exclude potentially false positive 
variants based on what is known about the MND. This sub-study is however still ongoing, and the 







Table 2: MND semantic terms to inform gene ontology BORG terms  





































Defects in axonal transport 
Defects in glial cell function 
Microglial activation 
RNA processing defects 
Neuronal protein aggregates 
(ubiquitin/TDP43/FUS) 
DNA/RNA binding proteins 
abnormalities 
Caspase activation 
Inactivation of excitatory 


















TARDBP (TAR DNA binding 
protein)  (associated with upper 
limb onset) 
FUS (fused in sarcoma) 
(associated with LMN 
predominance) 
SOD1 (superoxide dismutase 1) 
(associated with LMN 
predominance) 
C9Orf72 
ALS2 (amyotrophic lateral 
sclerosis 2) 
ANG (angiogenin) 
DAO (D-amino-acid oxidase) 
FIG4 
NEFH (neurofilament, heavy 
polypeptide 200kDa, heavy chain) 
OPTN (optineurin) 
SETX (senataxin) 
VAPB (vesicle associated 
membrane protein B and C) 
VCP (valosin containing protein) 













5.1 Ethical considerations 
 
Informed consent was taken from each participant in the study, for the inclusion of clinical data as 
well as for genetic analysis. Informed consent covered public sharing of genetic information should a 
variant be discovered. 
 
All patients received information on MND and whole exome sequencing, in their first language. 
 
Participants’ identity was kept confidential throughout the study, through the use of an assigned 
study identification code. The original consent documents and data capture sheets containing the 
patients’ names were kept in a locked office in the Division of Neurology, Groote Schuur Hospital. 
 
5.2 Ethics approval  
 
The University of Cape Town Human Research Ethics committee approved this study for a Masters in 






6. Results and discussion 
6.1 Systematic review  
 
Motor neuron disease in people of African descent: what is known? 
Background 
 
African genetic ancestry is ancient and diverse. Africa is thought to be the ancestral homeland of all 
modern humans according to evolutionary studies (Tishkoff and Williams, 2002). More recently, one 
of the largest migrations in human history was that of Africans (predominantly from West Africa) to 
Europe and the Americas as part of the slave trade, which resulted in African genes being 
transported to these areas and admixed with local indigenous genes, as well as those of other 
transcontinental migrants. African genetics and the possible role they play in complex diseases are 
therefore important areas for further research with more wide reaching consequences than may 
initially be considered. Additionally, as we understand more about the causation of disease, the role 
of environmental influence (possibly interacting with genetic susceptibility) becomes more 
important. Due to different socioeconomic and environmental factors, the environment in which 
most Africans live is vastly different to most individuals from first world Western countries. This 
could lead to epigenetic influences on genetic traits. For these reasons, the study of disease as it 
occurs in African populations has importance for us all.  
 
For those working in Africa, it is also critical to understand if our patients differ from those in other 
regions of the world in terms of phenotypic expression of disease. In all diseases, but especially 
those with a significant genetic contribution, the consideration of differing genetic ancestry in 
different study populations becomes important. The only way to study this fully is to collect data 
from our setting and compare it to that found in other populations. An important starting point is to 
consider what is already reported in the published literature. To this end, a systemic review of 
knowledge regarding motor neuron disease in people of African descent was undertaken. 
 
Review of the literature 
 
In order to identify studies on MND in African populations, a systematic search was conducted as 
outlined in the methods section. 
 
This search identified 36 research papers in total: 16 studies were original research from African 
countries, 11 studies were original research on mixed populations, not in Africa, but containing 
persons with African genetic ancestry, three papers were reviews or commentaries on MND in 
African populations, two papers were reviews on MND in groups with multiple different ethnic/racial 
populations, and four articles made mention of MND genetics in African people (See figure 3). 
Studies written in French were excluded, except for two where an English abstract was available. 
Mention was made in the reference lists of the above studies of six other reports on MND in Africa. 
These references could not be traced; however four out of six appeared to be in French. Studies 
reporting on spinal muscular atrophy and konzo were not considered. Although these disorders are 
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also a type of motor neuron pathology, they are not considered to be classic motor neuron disease 
and did not therefore form part of this study. 
 
Total papers reviewed (36)
Original studies in Africa (16)
• On MND specifically (13)
• On neurological disorders more broadly (3)
Reviews on MND in SS Africa (3)
Studies on MND with people of 
African ancestry (11)
Reviews on MND in groups with 
multiple racial populations (2)
Genetics of MND in Africans (4)
 
Figure 3: Papers reviewed for African MND systemic review 





Studies conducted on MND in Africa  
 
Papers reporting on 16 studies conducted on MND in Africa were analysed. 13 focussed specifically 
on MND, whereas three were on neurological or neurodegenerative disorders more broadly. The 
time span of publication was wide, and the majority of the papers (10) were published prior to 2000. 
 
The three reviews on MND in sub-Saharan Africa (Lekoubou et al., 2014, Marin et al., 2012, Quansah 
and Karikari, 2015) largely represented summaries of the above original papers and were used 










Table 3: African motor neuron disease studies 
Motor neuron disease specific Neurological/Neurodegenerative disorders  
non specific 











(Abdulla et al., 
1997) 
Sudan 28 C (Kengne et al., 
2006) 
Cameroon  10 C and 
E 




Nigeria NA E 
(Brah et al., 
2014)* 
Togo 5 C (Tekle-
Haimanot et al., 
1990) 
Ethiopia NA E 




86 C     
(Daude, 2014) South 
Africa  
48 C     




NA E     
(Eze and Kalu, 
2014)# 
Nigeria 1 E     
(Harries, 1956) Kenya 2 C     
(Imam and 
Gunniyi, 2004) 
Nigeria 16 C     
(Osuntokun et 
al., 1974) 
Nigeria 92 C     
(Radhakrishnan 
et al., 1986) 
Libya 23 C     
(Sene et al., 
2003)* 





13 C     
*Only abstract available – full paper in French and not accessible 
# Not useful studies – information too limited 
E= Studies rendering purely epidemiological type data such as rates and prevalences  
C= Studies rendering clinical information about disease presentation 
NA=not applicable (epidemiological studies looking at extrapolated rates of disease in a population) 
 
The above table summarises the African MND studies reviewed. The studies by Eze and Kalu and 
Dean and Elian will not be considered further. The paper by Dean examined relative rates of 
mortality due to MND in white South Africans, comparing those who were immigrant from Europe 
and those who were South African born (Dean and Elian, 1993). The paper by Eze looked at 
neurological admissions to a teaching hospital in Nigeria over a 1 year period. Only 1 case of MND 
was included, with no clinical information (Eze and Kalu, 2014). 
 
The first clinical report on MND in Africans described 2 cases seen in Kenya in 1954. Both cases were 
young (26 and 30 years), and both male, but otherwise had typical mixed upper and lower motor 
neuron signs involving the cranial, cervical and lumbosacral regions, with sparing of sensation and 




Two reports were published in the 1970s. In 1972 Wall described 13 cases from Rhodesia (now 
Zimbabwe). His report (based in the Department of Medicine, University Hospital) also indicated a 
young age of onset, mean 36 years, and a male predominance (10:3). He found no geographical 
clustering or familial cases. Typical mixed upper and lower motor neuron signs, with absence of 
sphincter involvement were described. One unusual feature he noted was sensory symptoms 
without signs in 6 of his patients. Of note, his patients had no spinal imaging or electrophysiological 
testing done (Wall and Gelfand, 1972).  
 
Osuntokun’s 1974 study from Nigeria, was the first prospective study on MND in an African 
population. It described all cases of ALS (73), progressive muscular atrophy (10) and chronic spinal 
muscular atrophy (9) diagnosed and followed up at University College Hospital, Ibadan, between 
1966 and 1973. Diagnoses were based on clinical, electrophysiological, imaging, blood, cerebrospinal 
fluid and muscle biopsy information. He described the three categories of motor neuron diseases 
separately. The ALS group had a mean onset of 39 years of age, with 23% younger than 30 years. The 
male to female ratio was 3:1. No significant familial cases, but four patients had had previous polio. 
Clinical presentation was typical for MND in the limbs, with 40/73 having additional prominent 
bulbar involvement. Four cases also had parkinsonian features. Survival was relatively long: 54% 
>6years, 29% >10 years and 8% >15 years. Osuntokun discussed possible reasons for this earlier age 
of onset with longer survival in his population, considering the role of the polio virus, dietary toxins, 
possible chronic organophosphate or lead poisoning and trauma. The progressive muscular atrophy 
group of ten patients had a mean age of onset of 37.8 years, and 6/10 patients survived longer than 
six years. The information on chronic spinal muscular atrophy will not be considered further 
(Osuntokun et al., 1974).  
 
Radhakrishnan et al also conducted a prospective study on motor neuron disease in Libya, published 
1986. He describes the Libyan population to be very mixed given its Mediterranean location: “less 
than 1% of the Benghazi population is pure black”. Radhakrishnan captured all cases from North 
Eastern Libya diagnosed with MND in a five year period. Diagnoses were based on clinical, 
electrophysiological, imaging and laboratory data; 23 cases included: 17 ALS, four progressive 
muscular atrophy and two progressive bulbar palsy. Mean age of onset was 47.4 years. Median 
survival was 42 months. There were no familial cases. Population data from the 1984 Libyan census 
was used to calculate an average incidence rate of MND at 0.89/100000 population/year 
(Radhakrishnan et al., 1986). 
 
The first South African MND study was that of Cosnett et al from 1989, which retrospectively 
analysed 86 patients with MND across various racial groups, including 59 black African patients. 
Across all the racial groups there was a male predominance – 3:2 in the black patients. Some 
interesting features included earlier mean age of onset amongst the black group (47.4 years versus 
54 years in the white and Indian groups) and a relatively greater proportion of bulbar palsy and 
progressive muscular atrophy amongst females, especially in the black group. 56% of the black 
patients with MND came from rural areas, which was higher than that for the average hospital 
population. The authors speculated whether this could have a causative link, possibly environmental 




Adam described 47 cases of MND over a 10 year period in Nairobi, Kenya, published 1992, with half 
of the cases collected prospectively. Again there was a male predominance (2.8:1), and all three 
major types of MND were described (ALS, progressive muscular atrophy and progressive bulbar 
palsy). Although a small study, they observed a bimodal age distribution, with peaks in the fourth 
and sixth decades of life. The younger group (30-39 years at onset) was unusual in that the patients 
experienced a rapid course of disease with 7/9 dead within a year of diagnosis (and the other two 
lost to follow up) (Adam, 1992).  
 
The first MND study from Sudan was published in 1997 by Abdulla et al. He described 28 patients 
diagnosed with MND at teaching hospitals over an 18 month period. Age range at onset was 13-84 
years, mean 40 years. If considered by ALS category, the progressive muscular atrophy group had 
the youngest age of onset at 26.5 years. This was the first African study to describe familial cases. 
There were four cases with family history of MND. These cases had even younger onset (mean age 
20.7 years) and they also all had sensorineural hearing loss (as did one of the sporadic cases). 
Overall, the commonest presentation of MND was with initial bilateral upper limb involvement 
(39%), followed by bulbar onset (21%). None of the patients had dementia or parkinsonism.  Survival 
data is not included for all the patients, but three survived longer than eight years (Abdulla et al., 
1997). 
 
Of the four studies post year 2000, three gave only limited information. Sene et al from Dakar 2003, 
wrote a retrospective review of the cases of MND at the University Hospital over eight years. Only 
the abstract was accessible, but it stated 33 cases were collected, with an age range of 16-77 years 
(Sene et al., 2003). Imam et al provided an “update” on MND in Nigeria: 16 further cases over a 20 
year period were described retrospectively, confirming the earlier reports of male predominance 
(here 15:1) and young age of onset (here 38.6 years mean). Trauma was reported as the most 
frequent risk factor (Imam and Gunniyi, 2004). Brah et al reported on MND cases from Lome in Togo. 
Apparently only 5 cases satisfying El Escorial criteria for definite ALS were diagnosed during a 10 year 
period out of 10 128 patients seen at the neurology department. The average age at onset was 49 
years, and the average duration of disease was 17.6 months. All cases were male (Brah et al., 2014). 
 
The latest series on MND in Africans comes from South Africa. Daude and Combrinck described the 
results of a folder review of 48 patients from a Cape Town teaching hospital over a five year period. 
This included 43 sporadic cases and five familial. The male to female ratio was 3:2. Different racial 
groups were represented: eight white patients, 11 black African patients and 29 mixed African 
genetic ancestry patients. The mean age of onset tended to be higher amongst the whites/ 
Caucasians (58.8 years) versus black African population (45.9 years). There appeared to be a 
disproportionate number of MND patients with a work history in the chemical or agricultural 
industries (19%) compared to estimated 8% exposed to chemicals in the overall workforce in 
Western Cape region (Daude, 2014). 
 
The three broader studies provided only epidemiological type data. Kengne et al audited case notes 
of degenerative brain disorders as a proportion of general neurological case consultations over a 
nine year period at the two main teaching hospitals in Yaounde, Cameroon. Degenerative brain 
disorders accounted for 4% of the total consultations, with ALS accounting for 12% of this subgroup. 
Of the ten ALS patients included, eight male and two female, the mean age at presentation was 50.9 
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years (Kengne et al., 2006). Osuntokun’s group from Nigeria conducted a community-based study via 
door-to-door survey in a small town with stable population of about 20000 people. Potential cases 
identified via screening questionnaire and basic evaluation, were investigated further by a 
neurologist at the local hospital (details not supplied by the authors). They found a crude prevalence 
ratio of 15/100000 for MND (Osuntokun et al., 1987). The study by Tekle-Haimanot et al was very 
similar, yet conducted in Ethiopia. They found an MND prevalence of 5/100000. All cases had onset 
before age 42 years (Tekle-Haimanot et al., 1990). 
 
In conclusion, the data from primary African MND studies is sparse, with most information coming 
from retrospective audits. There is therefore great need for prospective observational studies in 
Africa. 
 
Studies on MND in populations with multiple racial groups, including mixed African genetic ancestry 
 
Eleven original studies looking at MND in mixed populations were found via the search strategy: five 
European (Tomik et al., 2000, Rojas-Garcia et al., 2012, Gouveia and De Carvalho, 2007, Johnston et 
al., 2006, Elian and Dean, 1993), four from the USA (Rechtman et al., 2015, Noonan et al., 2005, 
Kazamel et al., 2013, Gundogdu et al., 2014) and two from other regions (Zaldivar et al., 2009, Drory 
and Artmonov, 2007). In addition two reviews were found which discussed variation in MND in 
different populations (Chancellor and Warlow, 1992, Cronin et al., 2007), but neither had additional 
information about African MND.  
 
Chancellor examined the epidemiology of adult onset MND in populations “across the world”. 
Although he did not consider African populations, he did note marked variability in incidence in 
different population groups and considered genetic and environmental factors as contributory 
(Chancellor and Warlow, 1992) Cronin et al reviewed several MND epidemiological studies. The 
African studies included have already been examined here in their original form (Cronin et al., 2007). 
 
Of the 11 original studies, five were found to render more information and will be considered in 
more detail. The earliest of these, conducted by Tomik et al in 2000, was a retrospective case control 
study from the King’s Motor Neuron Disease Care and Research Centre, London. It looked at 
phenotypic differences between black and white patients with MND. It included 15 black patients 
with West Africa/Caribbean ancestry with three age- and sex-matched white MND patients for each 
black case. These investigators found a four times higher chance in the black African group of 
presenting with the flail arm variant (OR 4.33, p=0.05). Other potentially interesting findings were no 
familial cases in the black African group (compared with four in the white group), and one African 
case with sensory symptoms without signs (Tomik et al., 2000). 
 
Drory et al. published a study from Israel in 2007, looking at the presentation of MND in various 
subpopulations with the same living environment but differing genetic ancestry. The study was a 
retrospective analysis of 374 sporadic ALS cases (ancestry: 211 Central and Eastern European, 53 
North African, 43 Oriental, 19 Balkan, 9 Arab and others). The North African group was 57% male, 
32% had initial bulbar presentation and mean age at onset was 52.4 years. The main differences 
found between the groups were significantly younger age at onset in the African and Arab groups, 




Kazamel et al in 2013, retrospectively assessed differences between black and white MND patients 
attending a clinic in Alabama, USA. They reviewed records of 207 patients (147 white and 60 black 
African-American) with a similar racial proportion to that found in the local population. The black 
group was significantly younger at onset of disease than the white group (55 years versus 61 years, p 
= 0.011), but there was no difference with respect to survival or clinical features. In both groups 
longer survival was linked to younger age (Kazamel et al., 2013). 
 
A study by Gundogdu et al. in Arkansas, USA in 2014 focused on a death certificate review to analyse 
the number of deaths due to MND by race. This information combined with clinic diagnostic rate 
statistics, showed a lower than expected rate of MND in the African American group, as compared to 
the local population racial demographics. The average age of onset was again significantly lower in 
the black group, and this group was found to be less functionally able at presentation. There were no 
familial cases among the black African group, compared with 8% of white cases (Gundogdu et al., 
2014). 
 
Rechtman et al conducted an epidemiological study of MND cases in different geographic locations 
across the US; 5883 cases were collected over a 3 year period via active case surveillance by 
neurologists (75% white, 9% black African American, 4% Asian, 12% other race). Using the 
population demographics for the studied areas, crude average annual incidence rates for ALS were 
calculated, with breakdown by racial group: 1.79/100000person-years (PY) for whites, 0.8/ 
100 000PY for blacks, and 0.76/100 000PY for Asians. In addition to this lower incidence rate, the 
black group were more likely to be younger than the other groups at disease onset (Rechtman et al., 
2015). 
 
Of the remaining studies, four rendered epidemiological data, largely relative rates of MND across 
racial groups. Noonan et al studied death registry data and compared variation in MND by 
demographic variables. African-Americans and Hispanics had considerably lower rates of mortality 
due to MND than Caucasians (Noonan et al., 2005). Zaldivar et al from Cuba found a lower mortality 
rate due to MND in a mixed race group, when compared to white and black Cubans (Zaldivar et al., 
2009). Johnston et al studied MND incidence rates by racial group in various parts of London. It was 
a small study, but suggested a lower proportion of black African cases than would be expected for 
the population size (Johnston et al., 2006) but another study performed later by Rojas-Garcia et al 
also from London, found no significant difference in the incidence of MND by racial group (Rojas-
Garcia et al., 2012).  
 
Gouveia et al from Portugal reviewed a case series of 27 young onset sporadic MND cases (onset less 
than 25 years): nine with black African ancestry, four Caucasian and 14 of uncertain race. These 
cases all had longer survival than typical MND, in addition most were male and presented with 
symmetrical limb involvement (either upper or lower). Some of the cases underwent post-mortem 
and unusual basophilic inclusions were found within motor neurons. It is suggested that this 
presentation may represent a subtype of MND (Gouveia and De Carvalho 2007). Although this is a 
small sample, there is a high representation of black African ancestry patients with this unusual 




The study by Elian and Dean was not considered further as it used only study participant name as a 
method of racial classification of these subjects (Elian and Dean, 1993). 
 
Johnston et al. highlighted an important point regarding studies of MND in mixed genetic ancestry 
populations, namely that numbers of cases can vary widely according to definitions and inclusion 
criteria. These factors are not standardised across studies, making comparative analysis difficult 
(Johnston et al., 2006). 
 
What is known about MND-associated genes in people of black African genetic ancestry? 
 
There was very limited literature on MND genetics in African people. Four studies mentioned known 
MND genes and people of African genetic descent. The earliest study was that of Guerreiro et al 
from 2008. This group looked at the frequency of TARDBP mutations in sporadic ALS. 279 ALS cases 
(Caucasian) were examined, as well as 806 neurologically normal controls of European descent and a 
further 173 African control samples. Overall no cases had the mutation of interest but Africans were 
found to have greater genetic variation in TARDBP; single nucleotide polymorphisms (SNP) were 
more common (6.8%) than in Caucasian controls (1.1%) consistent with ancient origins of African 
populations (Guerreiro et al., 2008). This finding of increased SNP variants in African populations 
compared to European and Asians was also reported by Schuster et al (Schuster et al., 2010).  
 
Kwiatkowski et al. first described the FUS mutation causing familial ALS in a family from Cape Verde 
Island, off the North African coast (Kwiatkowski et al., 2009). This FUS protein is a neuronal nuclear 
protein involved in DNA and RNA processing. In cases with a FUS mutation, the protein aggregated 
abnormally within the cytoplasm causing cellular dysfunction. This is a similar mechanism to what 
happens with TARDBP mutations.  
 
In 2011 DeJesus-Hernandez described a case of sporadic ALS with a VCP mutation in a patient of 
African-American descent (DeJesus-Hernandez et al., 2011). This gene encodes for a protein with 
multiple intracellular roles including autosome-phagosome degradation. The mutation was an amino 
acid substitution or non-synonomous SNP, and was felt to have a disease-causing role in their 
patient. Other VCP mutations had previously been described in ALS (Johnson et al., 2010).  
 
Garcia-Redondo et al published a paper looking at the frequency of the C9orf72 repeat expansion in 
Spanish ALS cases and controls. Further controls from different racial backgrounds were included 
including European, African, Chinese and Japanese individuals. The expansion was found in 27.1% of 
the familial ALS cases and 3.2% of the sporadic cases. None of the controls had the expansion. In 
addition, the haplotype flanking the genetic alteration was shared amongst the cases. Amongst the 
controls, this expansion-associated haplotype was noted to occur relatively commonly in the 
European group (8.9%), and the African group (5.6%) but much less commonly in the Asian groups 
(1.6%). The authors suggested the relatively high frequency of the expansion-associated haplotype 
suggested it was ancient and that different mutation events could have occurred independently on a 
similar background (opposite of a more recent founder-effect). They suggest that this haplotype 





No more specific genetic studies have been conducted in African populations with MND and 




On reviewing the available literature on MND as it occurs in Africans, it becomes apparent that little 
is really known. Although there are a few original studies, all are very small and most are very out 
dated. Study methods vary widely, and are not rigorously scientific in most instances. There is also 
potential overlap with other motor neuron disorders such as polio, konzo or spinal muscular atrophy 
(SMA), as some studies did not specifically exclude these disorders and these may account for the 
earlier age in onset and longer disease durations. There are no specific reports pertaining to the 
genetic investigation of  MND in African patients. 
  
In full consideration of the above, some points regarding MND in African patients may be concluded. 
Most of the studies reported younger age at onset of disease in people of African genetic ancestry. 
There also appeared to be a tendency to longer survival. The reasons for this are unclear, and may 
relate to mixed reporting of different types of motor neuron disorders, including for example SMA. 
There were a few reports suggesting reduced incidence of MND in African populations, but this was 
studied in indirect ways and could reflect ascertainment bias or poor access to resources. Rates of 
familial disease appeared lower than in Caucasian populations, but again this could be inaccurate 
given the small sample numbers and lack of clarity in how this was determined. Phenotypic 
differences were not widely examined. One study (Tomik et al., 2000) found an increased rate of flail 
arm variant in patients of African genetic ancestry, and another from Sudan (Abdulla et al., 1997) 
found bilateral upper limb involvement at presentation was most common. Bulbar presentations 
were also relatively common in two studies (Osuntokun et al., 1974, Cosnett et al., 1989). Two 
studies mentioned sensory symptoms without signs (Wall and Gelfand, 1972, Tomik et al., 2000), but 
again the numbers are extremely small and this could possibly reflect inaccurate diagnoses. In the 
absence of a definitive test for MND it is important that the diagnosis is reviewed in the face of 
unusual clinical findings. For example, a patient referred to Groote Schuur Hospital as a young-onset 
MND case was found to have severe motor neuropathy due to molecularly confirmed porphyria 
variegate (Albertyn et al., 2014). That said, more recently there have been reports of clinical, 
electrophysiological and pathological evidence of sensory nerve abnormalities in a minority of MND 
patients (Hammad et al., 2007, Nolano et al., 2016). 
 
It is therefore still unclear whether MND occurs differently in people of African genetic ancestry. To 
be able to answer this question, more, larger-scale prospective clinical and epidemiological studies 
on MND are required from all over Africa.   
 
Africa is a geographically vast area with distinct subpopulations, more broadly considered as 
Western, Eastern and Sub-Saharan Africa, but actually comprising more than 2000 different ethnic 
and language groups. Studies examining the mitochondrial and nuclear DNA from African 
populations indicate that Africa is the most genetically diverse region in the world (Tishkoff and 
Williams, 2002). Even within sub-Saharan Africa, a recent study showed that five individuals of 
Khoisan and Bantu origin, from South Africa and the greater Kalahari region, were more distinct 
from one another in terms of SNP than a person of European ancestry is from one of Asian ancestry 
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(Schuster et al., 2010). Therefore although it may be simplistic to group “Africans” into one group, 
the richness of the genetic ancestry of its peoples surely means a greater potential chance of 
uncovering new variants responsible for MND which may impact on the understanding of the 




6.2 Flail arm variant of motor neuron disease:  
Clinical phenotype description of a case series from the Western 
Cape 
 
During the time period March 2014 to September 2016, 45 patients attended the Groote Schuur 
Hospital MND clinic and were enrolled into the clinical research database and DNA repository. Of 
these, 15 were female and 30 male. Patients were asked to self-categorise according to South 
African census racial categories. 82% of clinic patients were of African genetic ancestry. Different 
MND subtypes were represented, including 69% amyotrophic lateral sclerosis, 7% progressive 
muscular atrophy, 9% primary lateral sclerosis, 2% progressive bulbar palsy and 13% flail arm variant 
(see figure 4, A). The mean age of onset in the flail arm variant group was compared to the rest of 
the MND subtypes as a group, but no significant difference was found (48 years vs 54 years, p=0.3) 
(see figure 4, B).   
 
The flail arm variant group will be described in further detail.  For the purposes of this report flail-
arm variant is defined as a form of lower motor neuron disease predominantly affecting bilateral 
proximal upper limbs, although possibly asymmetrically at onset. The clinical features remained 
























Figure 4: Relative proportions of MND subtypes at GSH MND clinic during study period (A) and 





This 40 year old male of mixed African genetic ancestry (M/A) first presented a few months after 
symptom onset, with a complaint of bilateral shoulder weakness. He described an initial difficulty 
with lifting heavy objects above the level of his neck which progressed gradually over six months to 
not being able to lift up lighter weight objects. There were no lower limb, bulbar, visual or sphincter 
symptoms. He had previously been diagnosed with hypertension and was controlled on treatment. 
The patient had no significant family history. 
 
On neurological examination, he was found to have normal higher functions and cranial nerves. In 
the motor examination, there was no neck weakness. The upper limbs showed normal tone on the 
right, but reduced tone on the left. In terms of reflexes, brachioradialis was reduced, biceps absent 
and triceps present. There was prominent proximal weakness bilaterally: shoulder abduction MRC 
grade 3 (out of 5) on the right, grade 2 on the left; elbows flexion/extension grade 3-4; distal grade 
5. The lower limbs had normal power, tone and reflexes. Sensation and coordination were intact.  
 
MRI scan of the brain and cervical spine were normal. Nerve conduction studies in the arms and legs 
were normal. Electromyography (EMG) of the left deltoid, biceps and first dorsal interosseus all 
showed large, polyphasic motor units with reduced recruitment. Only the deltoid and biceps showed 
spontaneous activity. Serum creatine phosphokinase was mildly elevated at 396 IU/L (normal < 180). 
Blood counts and other metabolic parameters were normal.  
 
A muscle biopsy showed changes consistent with a longstanding neurogenic degeneration. 
Molecular genetic testing excluded a SMA mutation of the SMN1 gene.  
 
A year later he reported ongoing deterioration and had to be medically boarded from work.  
Fasciculations were noted in the deltoid and biceps muscles but power remained stable for almost 2 
years although muscle wasting was increasingly prominent in the proximal arms.  
 
Approximately 5 years later the patient began to complain of tiredness in his legs on walking. 
Examination showed wasting of the shoulder girdle muscles, and loss of all upper limb reflexes. 
Power was grade 2 for shoulder abduction bilaterally, 1-2 for elbow flexion, elbow extension and 
wrist flexion were 3, and wrist extension 4. Finger power was grade 4. There was also mild hip 
flexion weakness (grade 4) but the other leg muscles had full power. Tone and reflexes in the legs 
were normal.  
 
The patient continues to be followed, now 7 years after the initial presentation. His proximal arm 
impairment (lower motor neuron) continues to dominate the presentation. Although he does have 


































Figure 5: Photographs (with patient permission) of case 1, illustrating the pattern of marked 




This 52 year male of M/A developed shoulder weakness starting on the left side, but with 
involvement of the right side within a few weeks. There was an initial fairly rapid deterioration over 
about 2 months with subsequent stabilisation. He had no difficulty with his hands or his lower limbs. 
There were also no bulbar or sphincter symptoms. The patient described parasthesiae in his right 
hand 2nd and 3rd fingers. He was otherwise systemically well. He had no prior medical history but had 
suffered previous trauma – a screwdriver accident in 1982 leading to the loss of his right eye and a 
motor vehicle accident in 2009 with a minor whiplash injury to the neck.   
 
On neurological examination, higher functions and cranial nerves examinations were normal except 
for the absent right eye. Motor examination showed marked wasting of the shoulder girdle muscles: 
both deltoids, pectoralis, supra- and infraspinatus muscles. Power in the arms ranged from MRC 
grade 2 for shoulder abduction to 4 at the elbows and 5 more distally. Supra- and infraspinatus 
power was graded at 3. Tone and reflexes in the upper limbs were normal. The lower limbs showed 
normal motor examination except for a reduced ankle reflex on the left side. Sensation was reduced 
over the middle 3 fingers of the right hand and the L5/S1 dermatome on the left side. 
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Further investigations showed MRI of the cervical spine and brachial plexus were normal without 
contrast enhancement. There was a mild disc prolapse at L5/S1. Nerve conduction studies showed a 
mildly prolonged distal latency in the right median sensory study consistent with carpal tunnel 
syndrome. EMG of the left deltoid and biceps showed spontaneous activity and chronic neurogenic 
changes in the motor units whereas trapezius and first dorsal interosseous were normal. Blood 
counts and metabolic parameters were normal. Serum creatine phosphokinase was 218 IU/L. 
Cerebrospinal fluid was normal.  
 
Approximately a year later the arm weakness had deteriorated slightly. The patient had also 
developed neck flexion weakness finding it difficult to lift his head up off the bed. There was early 
swallow difficulty but forced vital capacity (FVC) was >80% of expected (4.2 litres). Motor 
examination showed fasciculations in the deltoid, biceps, brachioradialis and forearms bilaterally. 
Reflexes were absent in the upper limbs. Neck flexion power was MRC grade 3 and extension 4. 
Shoulder abduction and elbow flexion were severely weak, albeit assymetrical. Distal arm power 
remained normal. Leg power was full.  
 
Approximately 2.5 years after symptoms onset the patient noted mild hand weakness (grade 4) and 
later symptoms in his legs but with no functional limitation and no objective findings. About 3.5 
years after symptom onset his dyspnoea on exertion increased, the FVC was 2.1 litres and there was 
mild dysarthria. Examination showed, the tongue was wasted and fasciculating. In the arms the 
wasting had progressed to involve the small muscles of the hands bilaterally. Power in the arms at 
the shoulders and elbows was 0, 2 at the wrists and 3-4 in the hands. The right leg had slightly 
increased tone with brisk knee reflexes and an upgoing plantar response on the right. Power was still 
normal in the legs. We were informed by the family that this patient died at home, approximately 4 




This patient 46 year M/A male presented with a 2 year history of gradual onset shoulder weakness. 
He was initially aware of left shoulder weakness and a few months later, he realised the right one 
was similarly involved. He had no lower limb or bulbar symptoms. He had no significant prior 
medical or family history. He did however have a heavy smoking history and had previously 
sustained tendon injuries to his hands. 
 
On neurological examination he had normal higher functions and cranial nerve examinations. In the 
motor examination, he had significant wasting of his shoulder girdle muscles bilaterally with 
fasciculations, especially triceps, biceps, deltoid, pectoralis and supra- and infraspinatus, but more 
prominent on the left side. There was some milder wasting of the small hand muscles. Tone was 
reduced in the left upper limb with absent or reduced jerks, and normal tone and reflexes on the 
right. Power was reduced proximally with shoulder abduction at 3 on the left and 4 on the right, 
elbow flexion, wrist flexion and extension and finger extension were 4 bilaterally. Elbow extension 
and finger flexion showed full power. The lower limb motor examination was normal. Sensory 




Nerve conduction studies showed reduced compound muscle action potential amplitudes in the 
studied upper and lower limb motor nerves (median, ulnar, tibial and peroneal) but normal proximal 
and distal conduction velocities. Electromyography of the deltoid, first dorsal interosseus, 
brachioradialis, tibialis anterior and masseter muscles showed active chronic denervation changes, 
and the rhomboidus major and orbicularis oris showed chronic neurogenic motor unit action 
potentials. Blood counts and metabolic parameters were normal. Cerebrospinal fluid was normal.   
 
The patient was next seen 18 months later and he remained without bulbar or lower limb 
symptoms. His power had deteriorated slowly – predominantly in the proximal arms, which now 
showed a MRC grade of 2 for shoulder abduction bilaterally. His lower limb examination was still 
normal. His FVC was mildly reduced at 3 litres.  
 
Four years after symptom onset he was still employed and working with his hands. He had however 
started to develop cramps in his lower limbs. His power grades remained the same but his upper 




This 53 year male of indigenous African genetic ancestry presented with proximal left arm weakness, 
which had been slowly progressive over 2 years. He had no significant prior medical or family 
history. There were no sensory nor lower limb nor bulbar symptoms. 
 
On general examination, he was considered to have gynaecomastia. His neurological examination of 
the higher functions and cranial nerves were normal. On motor examination of the upper limbs, 
despite unilateral symptoms, he had bilateral signs. He had asymmetrical wasting of the deltoids, 
biceps and triceps muscles (left > right). His tone was normal. Reflexes were normal in the right 
upper limb and absent in the left upper limb. Power was reduced bilaterally but asymmetrically: left 
proximal 1-2, distal 4+; right proximal 4, distal 5. His lower limb motor examination was normal.  
 
Motor and sensory nerve conduction studies of the left arm and leg were normal. Electromyography 
of the left deltoid, trapezius and thoracic paraspinal muscles showed no spontaneous activity but 
large polyphasic units with normal recruitment – mild chronic neurogenic change. MRI of the 
patient’s cervical spine showed no cause for the presentation. Blood counts and metabolic 
parameters were normal. Serum creatine phosphokinase was 358 IU/L. Cerebrospinal fluid was 
normal. Molecular genetic testing excluded an expanded CAG repeat in the androgen receptor gene 
responsible for X-linked bulbar-spinal muscular atrophy.  
 
The patient was seen again 3 years later. Now 5 years into his illness, his arm weakness had 
worsened and continued to dominate the presentation. He had however also developed respiratory 
muscle weakness and a whispering dysphonia on standing. On examination, he had normal bulbar 
muscle appearance and function, although chest expansion was poor with a weak cough. There was 
mild neck flexion weakness of 4+. His upper limbs showed markedly reduced tone with absent 
reflexes. Power at the shoulder, elbow and wrist was 0-1. Finger flexion and extension scored a 
power grade of 2. Motor examination of the lower limbs was normal besides very mild hip flexion 
weakness of 4+/5.   
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Six years after symptom onset the patient deteriorated dramatically. He developed worsened 
weakness of his neck, trunk and lower limbs and was largely bedbound with dyspnoea on lying flat 
and inability to cough. On examination he had poor air entry in both lung bases with poor chest 
expansion. He was dyspnoeic at rest. His speech was dysphonic, but not dysarthric. His tongue had a 
normal appearance, and he had normal facial power. His jaw jerk was brisk. The neck was weak in 
flexion and extension at grade 3. Motor examination in the upper limbs showed reduced tone, 
absent reflexes and no power in any muscle group. The lower limb motor examination showed 
normal tone, brisk reflexes at the knees and full power except for hip flexion which scored a grade 
4/5. The leg power had deteriorated further over the next few months to grade 3 at hip flexion and 4 





This 39 year male with M/A presented with mild weakness of his right shoulder which he had noted 
whilst weight lifting at gym for the past few months. He had no prior medical history, but had had 
previous injuries to both knees, sustained whilst playing soccer. 
 
He was noted to have atrophy of his right upper arm muscles, fasciculations in the shoulder girdle 
muscles and mild scapular winging. His tone and reflexes were normal. Power in the right arm 
showed moderate weakness in the shoulder girdle muscles and triceps, mild weakness of the biceps 
and wrist extensors, and minimal hand weakness. The rest of the examination was unremarkable. 
MRI of the brachial plexus was normal. EMG was conducted which showed chronic neurogenic 
changes in the motor units of right C5 and T1 innervated muscles, as well as the mid thoracic 
paraspinals. 
 
Two years after the initial symptom onset his right proximal arm weakness had become severe and 
the right arm reflexes were noted to be brisk. An MRI of his cervical spine showed mild degenerative 
disc changes but insufficient to explain his presentation. An MRI brain was normal. Four years later 
electrophysiological studies were repeated. Nerve conduction studies of the right arm were normal. 
EMG of multiple muscles in the right arm (deltoid, triceps, biceps and first dorsal interosseus) 
showed marked spontaneous activity and chronic neurogenic change of the motor units. EMG of the 
left deltoid also showed active and chronic neurogenic changes whereas only chronic changes were 
evident in the left first dorsal interosseous. EMG of right leg muscles (tibialis anterior and vastus 
lateralis) was normal.  
 
Seven years post symptom onset, he reported to have experienced a gradual decline over the years 
in right arm power (predominantly proximally). He could no longer lift his arm above his head and 
could not grip normally. He had also noted fasciculations and was suffering with cramps in this arm.  
His other limbs were asymptomatic, and he had no bulbar, sphincter or respiratory symptoms.    
 
He was found to be systemically well on examination and higher functions and cranial nerves were 
normal. On motor examination of the right arm, he had marked wasting and fasciculations around 
the right shoulder girdle, especially the rhomboids, deltoid, latissimus dorsi and pectoralis. Right arm 
tone was reduced, but reflexes were brisk. The Hoffman’s was negative. Power was reduced both 
31 
 
proximally (average MRC 3) and distally (average MRC 4). In the left arm he had subtle wasting of 
the left pectoralis, but all other parameters were normal. His lower limb motor examination was 
normal. Sensation was normal throughout.  
  
EMG was repeated and confirmed the findings of two years previously; spontaneous activity and 
chronic neurogenic change in the right deltoid, triceps and adductor digiti minimi; left deltoid 
showed chronic neurogenic change. Right and left leg sample EMG was normal.  
 
The patient returned for review approximately 12 years after symptom onset. He reported 
continued gradual decline in his right arm power. It was now markedly weak and wasted and had 
become functionally useless; he was using his left arm for all tasks. He had recently become aware 
that his head felt heavy, but had no difficulty in lifting it up from a supine position. He still had no 
symptoms in the left arm, either leg, bulbar or respiratory regions.  
 
On examination, he was generally well. His forced vital capacity was 4.4 litres. Higher functions and 
cranial nerves were intact. Neck flexion power was mildly reduced at 4+/5, with normal extension 
power. The right shoulder girdle was markedly wasted with florid fasciculations, as were the forearm 
muscles but the hand was relatively spared. In addition, there was mild wasting of the left deltoid 
with fasciculations. Power was also markedly reduced (grades 0-2) throughout the right arm. The left 
arm showed mild finger weakness (grade 4) but was otherwise strong. Tone was reduced in the right 
arm with very brisk reflexes and a positive Hoffman’s. Left arm tone and reflexes were normal.  
Sensation in the upper limbs was normal. Lower limb examination and gait were normal. A repeat 
MRI of the cervical spine again was non-contributory. A diagnosis of probable flail-arm variant of 
MND was reached despite the asymmetry of the signs. 
 
Interestingly, at this time he became aware of a positive family history (see figure 6). Two male 
cousins had been diagnosed with a generalised lower motor neuron predominant MND (progressive 
muscular atrophy). The one case had died of his illness after 7 years. He was negative for the 





















This 64 year M/A male presented with painless bilateral upper limb weakness, of slow progressive 
onset over the previous 3 years. Over the last year his hands had become weak as well, 
predominantly on the left side, which had limited his functional ability. There were no lower limb 
symptoms, nor respiratory nor bulbar symptoms.  
 
This patient first presented to the orthopaedics department, about two years after symptom onset, 
and was found to have significant multilevel degenerative spine disease. MRI showed significant 
spinal stenosis secondary to disc-osteophyte complexes C3-C7, with associated bilateral foraminal 
narrowing C3-C7 and mild cord compression C4/5 but no associated cord signal change. A C3-C6 
laminectomy was performed in early 2016, but despite marked interval improvement on repeat MR 
cervical spine imaging, the patients’ signs and symptoms continued to worsen. In addition, no 
sensory changes were ever present. He was therefore referred to neurology. 
 
On examination, the striking feature of the patient’s presentation was marked bilateral, symmetrical 
upper limb weakness and wasting, with hypotonic arms that were almost functionally useless. 
Reflexes were present in the upper limbs. Power was reduced to MRC grade 2/5 at shoulder 
abduction and elbow flexion/extension. Wrist power was 4/5, as was hand power on the right side. 
Left hand power was reduced to 2-3/5. Fasciculations were seen throughout the upper limbs. Neck 
power was only slightly reduced on flexion (4+/5). The lower limbs showed mild bilateral spasticity 
and hyperreflexia with extensor plantar responses. In addition, fasciculations were seen in the 
quadriceps and tibialis anterior muscles. Power in the lower limbs was full. Bulbar examination was 
normal. Sensation was intact throughout the body. Despite not having any respiratory symptoms, 
chest expansion was found to be decreased and FVC was 1.4L. 
 
Nerve conduction studies of the right peroneal and right median motor nerves showed mildly 
reduced amplitudes with normal conduction velocities. The right tibial and ulnar motor studies, 
including F responses were normal, as were upper and lower limb sensory studies. EMG of the right 
deltoid and first dorsal interosseus muscles showed active and chronic denervation changes. Similar 
findings were found in the right vastus lateralis, the thoracic paraspinals and the upper trapezius 
muscle. This study concluded widespread electrophysiological evidence of a motor neurogenic 
process. 
 
Although now three years into his illness and showing more widespread signs of motor neuron 
dysfunction, this patient’s symptoms remain limited to his arms, and the proximal arm weakness and 
wasting continue to dominate the presentation. It is felt therefore that a diagnosis of probable flail 
arm variant can be made. Also to consider is that the patient did have co-existent degenerative 















Pattern of arm 
weakness  
(time from onset, to 
onset contralateral UL) 
Pertinent clinical 




(prior to MND 
diagnosis) 
Electromyography studies 
(year from symptom onset) 
Appearance of UMN 
signs* or signs in other 
regions  
(years after symptom 
onset) 
1 40 years 
(2009) 
≥7years Nil B, P (0)  C5-C7 myotomal 




Limb girdle muscular 
dystrophy 
C5/C6 acute/chronic; C8/T1 
mild chronic neurogenic   
(1) 
Mild LL weakness (5) 
2 52 years 
(2012) 
4years Nil U, P, (2mo)  C4-C7 myotomal 




C5/C6 acute/chronic  
(1) 
mild neck weakness & 
bulbar symptoms (1) 
Thoracic signs (3) 
3 46 years 
(2011) 
≥ 5years Nil U, P (6mo)  C5-6 myotomal 
weakness and wasting  
 C5-T1 (acute/chronic); V 
cranial; L4/5 chronic 
neurogenic  
(2) 
UL UMN signs (3.5) 
4 53 years 
(2011) 
 7years Nil U, P (2 years) C5-T1 myotomal 




C3-5, T10 and cranial XI 
chronic neurogenic 
(2) 
thoracic signs and neck 
weakness; UMN signs 
bulbar and LL (5) 





U, P (10years) R side C4-C7 myotomal 




R C5-C8, T10 chronic 
neurogenic (1) 
C5-8 bilateral acute/chronic  
(12) 
UL UMN signs (2) 
Neck weakness (11) 
6 61years 
(2013) 







C5-8, T10, L3, cranial XI 
acute/chronic  
(3) 





Table 4: Summary of flail arm variant case features  

































Figure 8: Graphs showing relative loss of power in body regions over time for each of the 6 patients 
 
 
Discussion of the case series 
 
This collection of cases recruited from the Groote Schuur Hospital MND clinic between March 2014 
and September 2016, illustrate in an African cohort, the previously described features of flail arm 
variant of motor neuron disease (Hu et al., 1998, Wijesekera et al., 2009, Katz et al., 1999, Hübers et 
al., 2015, Couratier et al., 2000, Talman et al., 2009).  Although a seemingly clear phenotype, flail 
arm variant has to date been poorly characterised in terms of exact case definition, most likely in 
part due to the paucity of large published case series. The most widely used definition is that 
proposed by Wijesekera et al, which describes FA variant as a “lower motor neuron disorder of the 
upper limbs, characterized by progressive, predominantly proximal weakness and wasting with or 
without pathologic reflexes in the upper limbs, but excluding patients with hypertonia of the upper 
limbs, distal upper limb weakness or wasting without proximal involvement at presentation, and 
functionally significant weakness or wasting in lower limbs and bulbar musculature within 12 months 
of onset of upper limb symptoms.” (Wijesekera et al., 2009).  We conformed to this definition of the 
FA variant in collecting this case series.  
 
Within the GSH MND clinic, the FA variant cases represented 13% of the population during the study 
period. This is similar to other described cohorts, where the FA phenotype was found in 10% (Hu et 
al., 1998) and 6 and 11% (Wijesekera et al., 2009). In the series described by Katz et al., the FA 
variant cases made up only 2% of the overall cohort, but their inclusion criteria were more rigid (Katz 
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et al., 1999). Katz et al (Katz et al., 1999) are more restrictive in their definition, and define brachial 
amyotrophic diplegia (as they prefer to label the syndrome) as a pure lower motor neuron syndrome 
restricted to the upper limbs for at least 18 months, with the majority of patients having no signs 
outside of this region after a mean of 67 months. They propose that this group could perhaps rather 
be considered a variant of PMA than of ALS as a whole. Five of the cases in our series (cases 1,3,4,5) 
conform to this definition, with signs restricted to the upper limbs for at least 5 years from symptom 
onset.  
 
Hübers et al reported that they considered the phenotype to be that of predominantly proximal, 
symmetrical involvement of the upper limbs at presentation (rather than symptom onset), and 
found according to this definition that 40% of their 42 cases had distal upper limb onset, 36% distal 
and proximal onset and only 24% purely proximal onset (Hübers et al., 2015). All of our cases had 
onset proximally in the upper limbs, but on first examination, four had milder distal weakness and 
wasting as well, although in three this was very subtle.   
 
All of our cases were male which is in keeping with the previously noted male predominance (4-9:1) 
in all other described case series (Hu et al., 1998, Hübers et al., 2015, Katz et al., 1999, Wijesekera et 
al., 2009, Talman et al., 2009, Couratier et al., 2000, Tomik et al., 2000). This contrasts with the usual 
male to female ratio of 1.2:1 in typical ALS (Logroscino et al., 2008). 
 
None of GSH FA patients were Caucasian – rather five of mixed African genetic ancestry and another 
of indigenous-Xhosa African ancestry. In the literature regarding patients with African genetic 
ancestry phenotypic differences were not widely examined. One study (Tomik et al., 2000) found an 
increased rate of flail arm variant in patients of African genetic ancestry, and another from Sudan 
(Abdulla et al., 1997) found bilateral upper limb involvement at presentation to be most common. 
Our cohort is too small to detect a potential increased rate of this variant in people of African 
genetic ancestry. 
 
The FA variant patients in this series were mostly young on presentation (39-61 years, mean 
48years).  However the mean age of onset was not significantly different when compared to the rest 
of our MND cohort (48 vs 54 years, p=0.3). Other FA variant cohorts also describe similar age of 
onset to ALS (Hu et al., 1998, Katz et al., 1999). The typically quoted mean age range of onset for ALS 
is 58-63 years (Kiernan et al., 2011, Logroscino et al., 2008).  
 
Besides Katz et al, most of the published case series agree that upper motor neuron signs eventually 
develop in most patients over time. In this series four out of six patients developed upper motor 
signs with progression, but these were only detected ≥3 years after symptom onset. It is also 
generally agreed that spread to involve other spinal regions will eventually occur, although the 
predominant picture remains that of proximal upper limb weakness and wasting. In this series, in all 
patients, the proximal upper limb weakness and wasting continually dominated the presentation 
despite five out of six cases showing signs of spread of disease to other regions. There was marked 
variability in the time span over which this occurred (1-11 years).  Of note, the case with the earliest 
spread had the shortest survival. This is in line with the observation by Wijesekera et al. who noted 
that the FA phenotype is associated with a significantly improved survival, which appears to be 
linked to time to spread to the second region of involvement (Wijesekera et al., 2009). This was also 
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shown in the series described by Katz et al. where the majority of the patients remained well with 
restricted LMN findings in the upper limbs after 67 months of symptomatic disease (Katz et al., 
1999). 
 
FA variant patients have been shown to have longer survival than typical ALS in most cohorts 
(Talman et al., 2009, Wijesekera et al., 2009, Katz et al., 1999), with a trend to longer survival in the 
cohort described by Hu et al. (Hu et al., 1998). One series from Japan however describes five 
patients with otherwise typically presenting FA variant, but with rapid development of respiratory 
compromise and death within 20 months from symptom onset (Kataoka et al., 2010). The authors 
suggest that genetic differences may be the cause.  In the series described by Tomik et al., Caucasian 
FA patients are compared to FA patients with African genetic ancestry. The African ancestry patients 
displayed shorter survival than the Caucasian patients.  We were unable to make direct comparisons 
between racial groups as our series of FA variant patients contained only mixed African genetic 
ancestries. However, although we did find variation in survival times (4 years to more than 12 years), 
no patients experienced a rapid progression as described in the Japanese cohort. 
 
A case series from France (Couratier et al., 2000) showed the most common cause of death, as in 
other MND subtypes, to be respiratory failure. Interestingly though, in the FA patients, the majority 
of them had preserved independent ambulation despite respiratory failure. This is particularly 
interesting given the cervical origin of innervation of the diaphragm. Two of the patients in this 
series (cases 2 and 4) have died, presumably due to respiratory failure. Both cases were still 
independently ambulant at the time of death.  
 
Case 1 and case 3 in this current series are perhaps the best prototypical flail arm variant examples, 
with complete restriction of clinical symptoms and signs to the upper limbs (with marked proximal 
predominance) for five and four years respectively, at which point there was only mild involvement 
of other regions. Case 4 remained similarly restricted for 5 years, but thereafter experienced a more 
dramatic deterioration. Case 2 does meet criteria for flail arm variant (Wijesekera et al., 2009), in 
that symptoms remained restricted to bilateral symmetrical proximal arm weakness and wasting for 
15 months before spreading to other regions, and the arm involvement consistently dominated the 
presentation. He thereafter developed mild bulbar symptoms and later mild thoracic and lower limb 
symptoms too. One atypical feature in this patient is the mild neck weakness which became 
symptomatic early in the presentation (just 15 months post symptom onset). The neck muscles are 
supplied by nerves originating in the cervical plexus, which is also where the arm muscles are 
innervated from. This does therefore not necessarily imply that the pathology is more widespread 
than the cervical spinal segment earlier on. Early neck weakness is usually considered a poor 
prognostic sign (Nakamura et al., 2013). This patient remained ambulant with good speech and a 
relatively restricted disease pattern at three years into his illness, however despite this, he died 
about four years after symptom onset.  
 
Case 5 is an atypical form of flail arm variant given the marked asymmetry of his presentation. Yet it 
has become apparent over time that the other arm is also involved. This patient otherwise displays 
features typical of FA variant, given the lower motor neuron onset in the proximal arm muscles (with 
only much later development of brisk reflexes) and restricted phenotype over many years. 
Monomelic amyotrophy (Hirayama et al., 1963) was considered as a diagnostic possibility, but the 
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patient is much older than the age range described for this condition. Monomelic amyotrophy also 
typically affects muscles innervated by C7-T1, only very rarely has fasciculations and is a fairly benign 
disorder, not progressing beyond a few years. Case 3 and 4 were also notably asymmetrical at onset, 
although did become more symmetrical with time. Hübers et al describe a large proportion (76%) of 
the cases from their series have asymmetrical onset which becomes symmetrical later on (Hübers et 
al., 2015).  
 
The electrophysiological findings in cases 1 and 2 were restricted to the upper limbs muscles, and in 
fact only the proximal upper limb muscles in case 2. Cases 3, 4 and 6 showed more widespread 
abnormalities, on EMG in all cases and EMG and NCS in case 3 and 6. In these cases however the 
studies were done two to three years after initial symptom onset, whereas cases 1 and 2 had their 
studies done within a few months of symptom onset. This could illustrate a spread of pathology to 
other regions over time, but this is purely speculative. Interestingly case 5 had abnormal EMG of his 
mid-thoracic paraspinal muscles soon after symptom onset, although the most marked changes 
were in the symptomatic limb. Other FA case series which describe EMG findings (Sasaki, 2007, Yoon 
et al., 2014, Hu et al., 1998) also report more widespread chronic neurogenic change on EMG than is 
clinically apparent in terms of signs or symptoms. 
 
One interesting aspect highlighted in this exercise was the varied differential diagnostic 
considerations in these patients. Only in case 3 was motor neuron disease diagnosed at the first 
presentation, although flail arm variant was only recognised later. This could indicate that flail arm 
variant is less widely known, but could also indicate an understandable reluctance to diagnose motor 
neuron disease in less than typical cases. This finding is not isolated to our unit. Hübers et al also 
reported an initial misdiagnosis rate of 55% for the FA variant cases (Hübers et al., 2015). They raise 
the point that this is detrimental, as many patients are being exposed to costly, ineffective and 
potentially harmful treatments – typically intravenous immunoglobulins for a  misdiagnosis of 
multifocal motor neuropathy. 
 
Case 6 is unusual in that he had definite co-morbid degenerative spine disease requiring 
decompressive surgery. It was only after this was corrected and the patient continued to deteriorate 
that an additional diagnosis of MND was made. It is not possible to determine how much the co-
morbid condition influenced the presentation of MND. This situation is not unusual given how 
common degenerative spine disease is, and that the typical age of onset range overlaps with that of 
MND. A study from Japan found that 48% of ALS cases are complicated by co-morbid cervical 
spondylosis (Yamada et al., 2003). Another diagnostic consideration is cervical spondylotic 
amyotrophy, which is due to degenerative spine disease, presenting (usually unilaterally although 
bilaterally also described) with upper limb weakness and wasting affecting either proximal or distal 
muscles without sensory impairment or lower extremity dysfunction. MRI may show T2 
hyperintensity within the cervical cord. There are two hypotheses about cause in this condition: 
either selective intradural ventral nerve root compression by posterolateral osteophytes, or vascular 
insufficiency resulting from dynamic cord compression.  Autopsy studies have shown normal 
anterior horn cells, with selective intradural ventral nerve root compression. Cervical spondylotic 
amyotrophy is described to be clinically indistinguishable from FA MND in the early stages, but by 
three years, symptoms or electrophysiological changes should be present in other regions in the 




Genetic studies at our MND clinic are not routinely performed, however we have recently been able 
to test all our existing clinic patients for the C9orf72 mutation. In people of European genetic 
ancestry, this mutation is known to 40% of familial ALS cases and 7% of sporadic cases (Majounie et 
al., 2012). In a much smaller sample of sporadic ALS cases in persons with African genetic ancestry, 
C9orf72 mutation was found in 4% (Majounie et al., 2012). None of our cases tested positive for the 
mutation. (This could perhaps have been expected as the described mutations cause typical ALS; FA 
variant in association with C9orf72 mutation has not been reported.) Further genetic studies are 
planned, including WES on two of these FA patients, including one family trio (as mentioned briefly 
in the methods section). The WES technique has recently been shown to be successful in detecting 
potential causative mutations in a familial FA variant: the study by Liu et al. describes a novel 
missense mutation in hnRNPA1 in a large affected family (Liu et al., 2016). Other known MND genes 
with mutations previously linked to lower motor neuron presentations include SOD1 and FUS (Ravits 
et al., 2013, Blair et al., 2010). A specific TARDBP mutation has been described for FA variant (Solski 
et al., 2012). These genes will be investigated further in our cohort at a later stage. 
 
The two main limitations of this descriptive case series are the small size and its retrospective 
nature. Although the cases were identified amongst clinic attendees during a fixed time period, none 
of them were new presentations. This meant that information regarding the initial presentations, 
including examination and electrophysiological findings, were limited to that recorded in the 
patients’ files. Additionally, the patients were differently investigated according to attending 
consultant opinions and varying differential diagnostic considerations.  It did however enable the 
investigator to appreciate their progression over time.  MND is a rare disorder, and the FA variant is 
only seen in a small proportion of cases. A larger case series would need to be collected over several 
years, ideally at multiple centres.  
 
In conclusion, our case series illustrates the FA variant – a distinct MND phenotype with onset in the 
proximal upper limbs, predominantly lower motor neuron signs and a protracted course in most 
patients, which does seem to largely be linked to the extent of clinically apparent regional 
involvement. Katz et al.(Katz et al., 1999) felt that this variant should be limited to those patients 
with pure LMN involvement, restricted to the upper limbs for at least 18 months, but typically much 
longer. This subgroup does seem to have improved overall survival. The more inclusive definition 
proposed by Wijesekera et al. (Wijesekera et al., 2009) does however still have merit, as this 
phenotype does differ from other ALS cases in that ambulation remains spared until late, and the 
majority do experience a longer survival. We are limited by purely clinical definitions however, and 
perhaps MND pathology occurs as a spectrum rather than in discrete categories, making distinct 
classification difficult in some cases. We should however by aware that when counselling patients on 
prognosis, the greatly improved survival might only be relevant to those conforming to the stricter 
definition of FA variant as a persistently upper limb restricted, purely lower motor neuron variant.  
 
With regards FA variant in patients of African genetic ancestry, with the current available 
information, we cannot yet comment on whether this variant occurs more commonly, but we can 
say that it occurs in a similar manner to that described for Caucasian populations. Larger studies 







7. Conclusions and recommendations 
 
Considered in its entirety, this work has highlighted several important points regarding motor 
neuron disease, especially as it occurs in the African context. 
 
More research is required on primary African populations to address the questions surrounding 
MND as it occurs in Africans, including phenotypic and genetic similarities or differences to other 
populations. A large prospective clinical study is currently underway at Groote Schuur and Tygerberg 
Hospitals to describe the incidence, clinical features and longitudinal course of motor neuron disease 
in the Western Cape.     
 
Although controversy surrounding exact case definitions of the flail arm variant of MND remain, with 
further elucidation of underlying genetic and pathogenic mechanisms, the reasons for the 
phenotype and its prolonged survival may become clearer. 
 
The genetics of motor neuron disease is still incompletely understood, but is currently a popular 
research topic, especially since the advent of next generation sequencing. Given the complexities 
involved, international collaboration with pooling of results is required to make the most of current 
knowledge and enable future progression. Further genetic studies are planned at Groote Schuur 
Hospital. We are currently building a DNA repository of all patients attending the MND clinic, with 
associated clinical findings, which will greatly assist in further genetic studies in our African MND 
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